Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer
Yago Nieto(The University of Texas MD Anderson Cancer Center), Scott I. Bearman(University of Washington), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Anna E. Barón(Colorado School of Public Health), Peter A. McSweeney(Mesoblast (United States)), Samia Nawaz(University of Colorado Boulder), Steve Matthes(University of Colorado Boulder), Roy B. Jones(The University of Texas MD Anderson Cancer Center), Pablo J. Cagnoni(University of Colorado Hospital), Carrington Razook(University of Colorado Boulder)
Cited by 64
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k